Back to Search
Start Over
1017P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC).
- Source :
-
Annals of Oncology . 2022 Supplement 7, Vol. 33, pS1019-S1019. 1p. - Publication Year :
- 2022
- Subjects :
- *NON-small-cell lung carcinoma
*CANCER chemotherapy
*METASTASIS
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 159077928
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.07.1143